+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Endocrine And Metabolic Disorders Drugs Market Research Reports

From
Diabetic Gastroparesis - Pipeline Insight, 2025 - Product Thumbnail Image

Diabetic Gastroparesis - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Hypertriglyceridemia - Pipeline Insight, 2025 - Product Thumbnail Image

Hypertriglyceridemia - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 80 Pages
  • Global
From
Adenosine A1 Receptor Agonist - Pipeline Insight, 2025 - Product Thumbnail Image

Adenosine A1 Receptor Agonist - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Glucagon Receptor Antagonist - Pipeline Insight, 2025 - Product Thumbnail Image

Glucagon Receptor Antagonist - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Adenosine A2A Receptor Antagonist - Pipeline Insight, 2025 - Product Thumbnail Image

Adenosine A2A Receptor Antagonist - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
From
Androgen Antagonist - Pipeline Insight, 2025 - Product Thumbnail Image

Androgen Antagonist - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 90 Pages
  • Global
From
From
From
Growth Hormone Antagonist - Pipeline Insight, 2025 - Product Thumbnail Image

Growth Hormone Antagonist - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Insulin Like Growth Factor (IGF) Inhibitor - Pipeline Insight, 2025 - Product Thumbnail Image

Insulin Like Growth Factor (IGF) Inhibitor - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Adenosine A1 Receptor Antagonist - Pipeline Insight, 2025 - Product Thumbnail Image

Adenosine A1 Receptor Antagonist - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
From
From
Fabry Disease - Pipeline Insight, 2025 - Product Thumbnail Image

Fabry Disease - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 50 Pages
  • Global
From
Nephropathic Cystinosis - Pipeline Insight, 2025 - Product Thumbnail Image

Nephropathic Cystinosis - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Niemann-Pick Disease - Pipeline Insight, 2025 - Product Thumbnail Image

Niemann-Pick Disease - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Cystinosis- Pipeline Insight, 2025 - Product Thumbnail Image

Cystinosis- Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Diabetic Kidney Disease (DKD) - Pipeline Insight, 2025 - Product Thumbnail Image

Diabetic Kidney Disease (DKD) - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Loading Indicator

The Endocrine and Metabolic Disorders Drugs market is a segment of the pharmaceutical industry that focuses on the development and production of drugs used to treat endocrine and metabolic disorders. Endocrine disorders are conditions that affect the body's hormones, while metabolic disorders are conditions that affect the body's ability to process and use energy. Endocrine and metabolic disorders can include diabetes, thyroid disorders, obesity, and adrenal disorders. Endocrine and Metabolic Disorders Drugs are typically developed by pharmaceutical companies and are prescribed by physicians. These drugs can be used to treat a variety of endocrine and metabolic disorders, including diabetes, thyroid disorders, obesity, and adrenal disorders. Common drugs used to treat these conditions include insulin, metformin, and glucagon-like peptide-1 (GLP-1) agonists. Some of the major companies in the Endocrine and Metabolic Disorders Drugs market include Novo Nordisk, Sanofi, Eli Lilly, Merck, and AstraZeneca. These companies are involved in the development, production, and marketing of drugs used to treat endocrine and metabolic disorders. Show Less Read more